Apogee Therapeutics secured up to $1.3 billion in non-dilutive financing from Blackstone Life Sciences to advance zumilokibart (zumi) into Phase 3 for atopic dermatitis. The funding package follows additional efficacy signals from the biotech’s Phase 2 program, including reported data in moderate-to-severe disease. The deal provides runway for potential commercialization and supports a time-sensitive development push while Apogee continues to build evidence toward a potential label-defining trial. Apogee is also positioning its anti–IL-13 approach as a competitor in the crowded atopic dermatitis market. Near-term scrutiny will center on whether Phase 3 outcomes replicate Phase 2 performance and how the program differentiates versus existing biologics targeting established inflammatory pathways.